Biogen | BIIB - Interest Income


Biogen reported $37.9M in Interest Income for its fiscal quarter ending in March of 2026.





Interest Income Change Date
AbbVie USD 59M 13M Dec/2025
Acadia Pharmaceuticals USD 8.33M 86K Dec/2025
ALKERMES USD 8.54M 3.59M Mar/2026
Bayer EUR 169M 39M Dec/2025
Biogen USD 37.9M 700K Mar/2026
BioMarin Pharmaceutical USD 22.56M 3.35M Mar/2026
Eli Lilly USD 65M 25M Sep/2025
Esperion Therapeutics USD -0.15 0.18 Sep/2024
Gilead Sciences USD 95M 7M Dec/2025
Incyte USD 33.69M 2.93M Mar/2026
Merck USD 69M 27M Dec/2025
Moderna USD 70M 3M Dec/2025
Pfizer USD 115M 51M Mar/2026
Puma Biotechnology USD 0.41 0.5 Sep/2024
Regeneron Pharmaceuticals USD 193.3M 18.2M Dec/2025
Sanofi EUR 33M 81M Dec/2025
Sanofi EUR 114M 38M Sep/2025
Sarepta Therapeutics USD 8.74M 359K Dec/2025
Ultragenyx Pharmaceutical USD 6.51M 649K Dec/2025
United Therapeutics USD 43.2M 3.2M Dec/2025
Vertex Pharmaceuticals USD 114.8M 7.1M Mar/2026